Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Cantor Fitzgerald
Fish and Richardson
US Department of Justice
QuintilesIMS
Covington
Deloitte
Teva
Express Scripts

Generated: April 22, 2018

DrugPatentWatch Database Preview

RENORMAX Drug Profile

« Back to Dashboard

When do Renormax patents expire, and when can generic versions of Renormax launch?

Renormax is a drug marketed by Schering and is included in one NDA.

The generic ingredient in RENORMAX is spirapril hydrochloride. Additional details are available on the spirapril hydrochloride profile page.
Summary for RENORMAX
US Patents:0
Applicants:1
NDAs:1
Bulk Api Vendors: 10
Patent Applications: 238
Drug Prices:see details
DailyMed Link:RENORMAX at DailyMed
Drug patent expirations by year for RENORMAX
Synonyms for RENORMAX
(2S)-3-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-6,9-dithia-3-azaspiro[4.4]nonane-2-carboxylic acid hydrochloride
(8S)-7((S)-N-((S)-1-Carboxy-3-phenylpropyl)alanyl)-1,4-dithia-7-azaspiro(4.4)nonane-8-carboxylic acid, 1-ethyl ester, monohydrochloride
1,4-dithia-7-azaspiro(4,4)nonane-8-carboxylic acid, 7-(2-((1-ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)-,monohydrochloride, (8S-(7(R*(R*)),8R*))-
1,4-Dithia-7-azaspiro(4.4)nonane-8-carboxylic acid, 7-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)-, monohydrochloride, (8S-(7(R*(R*)),8R*))-
102657-EP2270011A1
102657-EP2272841A1
102657-EP2277879A1
102657-EP2287165A2
102657-EP2287166A2
102657-EP2292620A2
102657-EP2301936A1
94841-17-5
AC1OA87D
AKOS025311425
API0008088
C22H30N2O5S2.HCl
CAS-94841-17-5
CHEMBL1200831
D03765
DSSTox_CID_24272
DSSTox_GSID_44272
DSSTox_RID_80139
DTXSID6044272
LS-178246
NCGC00182545-01
OCC25LM897
Renormax (TN)
Renpress
Sandopril
Sch 33844
SCHEMBL387353
Spirapril HCl
Spirapril hydrochloride
Spirapril hydrochloride (USAN)
Spirapril hydrochloride [USAN]
TI 211-950
Tox21_112981
UNII-OCC25LM897

US Patents and Regulatory Information for RENORMAX

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Schering RENORMAX spirapril hydrochloride TABLET;ORAL 020240-001 Dec 29, 1994 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Schering RENORMAX spirapril hydrochloride TABLET;ORAL 020240-004 Dec 29, 1994 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Schering RENORMAX spirapril hydrochloride TABLET;ORAL 020240-002 Dec 29, 1994 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Schering RENORMAX spirapril hydrochloride TABLET;ORAL 020240-003 Dec 29, 1994 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for RENORMAX

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Schering RENORMAX spirapril hydrochloride TABLET;ORAL 020240-003 Dec 29, 1994 ➤ Sign Up ➤ Sign Up
Schering RENORMAX spirapril hydrochloride TABLET;ORAL 020240-004 Dec 29, 1994 ➤ Sign Up ➤ Sign Up
Schering RENORMAX spirapril hydrochloride TABLET;ORAL 020240-001 Dec 29, 1994 ➤ Sign Up ➤ Sign Up
Schering RENORMAX spirapril hydrochloride TABLET;ORAL 020240-002 Dec 29, 1994 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
Chubb
Cantor Fitzgerald
Deloitte
Accenture
Daiichi Sankyo
Citi
Teva
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.